Brief: Gracell Biotechnologies To Be Acquired By Astrazeneca, Furthering Cell Therapy Ambition Across Oncology And Autoimmune Diseases
26/12/2023 07:03
Dec 26 (Reuters) - Gracell Biotechnologies Inc GRCL.O :
* GRACELL BIOTECHNOLOGIES TO BE ACQUIRED BY ASTRAZENECA,
FURTHERING CELL THERAPY AMBITION ACROSS ONCOLOGY AND AUTOIMMUNE
DISEASES
* GRACELL BIOTECHNOLOGIES - SHAREHOLDERS TO RECEIVE $2.00
PER
ORDINARY SHARE (EQUIVALENT TO $10 PER AMERICAN DEPOSITARY SHARE
(ADS)) IN CASH AT CLOSING
* GRACELL BIOTECHNOLOGIES INC - DEAL REPRESENTING A TOTAL
TRANSACTION VALUE OF UP TO $1.2 BILLION INCLUDING CVR
Source text for Eikon: ID:nGNX89ZPDF
Further company coverage: GRCL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Gracell Biotechnologies
See all newsBrief: Gracell Biotechnologies Announces Shareholders’ Approval Of Merger Agreement
Brief: Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma
Newscasts - UK Day Ahead: European shares start last week of 2023 on strong footing
Live Markets: European futures rise after holiday break
Press Digest: British Business - Dec 27